Three-dimensional QSAR studies for substituted aryloxazolidinones 3-9 were conducted using TSAR 3.3. The in vitro activities (MICs) of the compounds against Staphylococcus aureus and Enterococcus faecalis exhibited a good correlation with the prediction made by the model using heat of formation and LUMO energies.
Introduction
Multidrug resistant Gram-positive bacteria continue to pose challenges to the medicinal chemistry community.
1 Linezolid 1, marketed as Zyvox ® , is an oxazolidinone class of antibacterial, approved for treating mostly Gram-positive bacterial infections, especially methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus Epidermidis (MRSE) and vancomycin resistant enterococci (VRE). 2 Another early clinical candidate, Eperezolid 2, was discontinued from development after phase I clinical trials. While much research has been aimed at the development of novel oxazolidinones, no new members of this class have achieved regulatory approval. In the past, some efforts have been made to understand the structure-activity relationships of oxazolidinone antibacterial agents using comparative molecular field analysis (CoMFA), 3D-QSAR and QSPR methods. 3 We have already reported 3D-QSAR studies for N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones 3-7 using TSAR 3.3. 4 The in vitro antibacterial activities (MICs) of compounds 3-7 against Staphylococcus aureus ATCC 25923 exhibited a strong correlation with the prediction made by our model. It was observed that the activity of the compounds increases when the energy of the LUMO (Lowest Unoccupied Molecular Orbital) is lower and the heat of formation (HOF) is higher. Thus, compounds which have lower HOF become less active and, similarly, compounds having low LUMO energies are the most active and the activity decreases as the LUMO energy increases. We decided to examine if our model (Equation 1) 4 can predict the antibacterial activity trends of different sets of compounds 8-9 for the same strain (S. aureus ATCC 25923) as well as in a different strain such as Enterococcus faecalis (E. fa) ATCC 29212. Log (1/C) = 0.006919662*HOF -0.72196823*LUMO -0.034151886*Polarization YY + 0.0004945533*Octupole XYZ + 4.8290181 (1) The present study aims to validate if compounds 8-9 follow the same parameters for the prediction of their activity, namely, that lower HOF and lower LUMO energies result in more potent antibacterial compounds.
Results and Discussion
Based on Equation 1, developed using the training set of compounds reported earlier by us, 4 calculations were done for a set of parameters for compounds 8a to 8aa, which is shown in Table  1 . A reasonable correlation between the predicted MICs by Equation 1 and the experimental MICs reported by Das et al. 5 was observed.
The predicted MICs, especially for 8h, 8i, 8j, 8m, 8n, 8q, 8r and 8u, were found to be 8-to 16-fold different from the experimental values. In view of the fact that, generally, reported MICs may vary from laboratory to laboratory by a factor of one dilution (i.e. 2 to 4 or 4 to 8), but some of the above compounds (8h, 8i, 8j, 8m and 8r) needed special deliberation.
Therefore, a new equation (Equation 2) was developed using randomly selected compounds from the training set shown in Table 1 Table 1 ).
We also considered that it would be interesting to study if Equation 1 can predict the activity of compounds with a different structural scaffold. Therefore, a study of compounds 9a to 9ac, as reported by Jang et al. 6 (Table 2) , was undertaken. A very good correlation between the predicted MIC using Equation 1 and the observed MIC (compound 9d to 9ac) was found, except for compounds 9a-9c (observed MIC >64 µg/mL versus predicted MIC 2-3 µg/mL). Another equation was developed using 23 compounds listed in Table 2 as training set in order to predict the MIC of the remaining test compounds 9m, 9o, 9s, 9v, 9ab and 9ac. However, the data sets are not suited for QSAR analysis because they have significantly different R 1 residues and 15 compounds have very small variance in the biological activities. However, we wanted to investigate if compounds with a different scaffold that have antibacterial activities follow a trend based on HOF and LUMO energies. The 3D QSAR model developed is as follows: Log (1/C) = 0.0070*X1 -3.1117*X2 -0.1317*X3 + 9.3684 (3) where X1 is Heat of Formation, X2 is LUMO and X3 is Polarization YY and the statistical parameters for above Equation 3 are: s value = 0.4182; F = 34.5641; regression coefficient r = 0.9193; r^2 = 0.8451; cross validation, r^2(CV) = 0.7246. 
The constant term in Equation 3
is dominant. Therefore, it is instructive to look at the molecular descriptors, based on t value, in the regression model. Descriptors with large |t| values are important in the predictive model and, as such, can be examined in order to gain some understanding of the nature of the property or activity of interest. The descriptors which had higher t-values and which appeared with higher frequency in previous models were selected to derive the final regression model. Table 3 indicates the statistical significance of descriptors HOF, LUMO and Polarization YY used in the derivation of Equation 3. Table 2 . We found an excellent correlation between the predicted and observed MICs. In all three equations we see a good correlation of activity with HOF and LUMO energies. Therefore, we made plots of C*HOF versus C*LUMO based on Equation 2, where C is a constant coefficient for compounds 8a-8aa (Figure 1) , and for compounds 8a-8ac based on Equation 3 (Figure 2 ). It can be observed in these figures that all the compounds that have high HOF and low LUMO energies always have superior antibacterial activities.
Encouraged by these results, a similar equation (Equation 4) for Enterococcus faecalis (E. fa) ATCC 29212 was developed using randomly selected analogues of compounds 8 and 9 in the training set. Compounds 8c, 8f, 8h, 8l, 8z, 9e, 9h, 9k, 9r and 9x Once again, a very good correlation between the predicted log (1/C) using Equation 4 and the observed log (1/C) was observed for compounds 8 as well as 9 against E. fa ATCC 29212. The results are summarised in Tables 1 and 2 . The correlation between the observed and the predicted antibacterial activities for the training set and the test set for compounds 8 and 9 using Equation 4 is shown in Figure 3 . It was expected that such a good correlation between observed and predicted antibacterial activities will also exhibit a close correlation with HOF and LUMO energies. An analysis of the plots of C*HOF vs C*LUMO (figure and values calculated for C*HOF and C*LUMO from Equation 4 are not shown in Tables 1 and 2 ), where C is a constant coefficient, for compound 8 and compound 9 for E. fa ATCC 29212, clearly suggests that for both sets of compounds as the C*HOF increases and C*LUMO decreases, the antibacterial potency of compounds improves and lower MIC values are observed.
It would be worthwhile to examine the antibacterial activities of compounds 3-7 in E. fa ATCC 29212 and verify if the values predicted (see Table 4 ) with Equation 4 are comparable to the observed MICs. However, to date there is no antibacterial activity data reported for compounds 3-7 for E. fa ATCC 29212. 
